RECRUITING

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Talk to us

Conditions

Hidradenitis Suppurativaskin diseaseruxolitinb cream

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to evaluate the maximal use of ruxolitinib cream in adult and adolescent participants with hidradenitis suppurativa.

Official Title

A Maximal Use Trial of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Quick Facts

Study Start:2025-09-15
Study Completion:2026-12-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT07049575

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:12 Years to 75 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of HS for at least 6 months before screening visit.
  2. * Diagnosis of HS (Hurley Stage I, II, III) with a total abscess and inflammatory nodule count of at least 4 and affecting at least 3 distinct anatomical areas at screening and Day 1 visits.
  3. * Total estimated treatment BSA \> 20% at screening and baseline.
  4. * Agreement to not use topical or systemic antibiotics for treatment of HS during the Maximal Use Treatment Period.
  5. * Willingness to avoid pregnancy or fathering children based on the criteria defined in the protocol.
  6. * Further inclusion criteria apply.
  1. * Current or history of skin condition(s) other than HS that might confound the evaluation of HS; clinically uncontrolled cardiovascular disease; thrombosis; certain cancers; certain infections; severe anemia, thrombocytopenia, or neutropenia; other medical conditions at the discretion of the investigator.
  2. * Laboratory values outside of the protocol-defined ranges.
  3. * Further exclusion criteria apply.

Contacts and Locations

Study Contact

Incyte Corporation Call Center (US)
CONTACT
1.855.463.3463
medinfo@incyte.com
Incyte Corporation Call Center (ex-US)
CONTACT
+800 00027423
eumedinfo@incyte.com

Principal Investigator

Incyte Medical Monitor
STUDY_DIRECTOR
Incyte Corporation

Study Locations (Sites)

Saguaro Dermatology
Phoenix, Arizona, 85008
United States
First Oc Dermatology
Fountain Valley, California, 92708
United States
Clinical Trials Research Institute
Newbury Park, California, 91320
United States
Amicis Research Center
Northridge, California, 91324
United States
International Clinical Research Us Llc Sanford
Sanford, Florida, 32771
United States
Lenus Research Medical Group, Llc
Sweetwater, Florida, 33172
United States
Trueblue Clinical Research
Tampa, Florida, 33609
United States
Emory University Dermatology Research Department
Atlanta, Georgia, 30322
United States
Lane Dermatology and Dermatologic Surgery
Columbus, Georgia, 31904
United States
Equity Medical, Llc
Bowling Green, Kentucky, 42104
United States
Delricht Research
Baton Rouge, Louisiana, 70809
United States
Revival Research Institute, Llc Dermatology
Troy, Michigan, 48084
United States
Red River Research Partners
Bolivar, Missouri, 65613
United States
Dr Bobby Buka, Md Greenwich Village
New York, New York, 10012
United States
Equity Medical, Llc
New York, New York, 10023
United States
Red River Research Partners
Fargo, North Dakota, 58103
United States
Centricity Research Columbus Ohio Multispecialty Office
Columbus, Ohio, 43213
United States
Unity Clinical Research
Oklahoma City, Oklahoma, 73118
United States
Paddington Testing Co Inc
Philadelphia, Pennsylvania, 19103
United States
Dermresearch, Inc.
Austin, Texas, 78759
United States

Collaborators and Investigators

Sponsor: Incyte Corporation

  • Incyte Medical Monitor, STUDY_DIRECTOR, Incyte Corporation

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-09-15
Study Completion Date2026-12-09

Study Record Updates

Study Start Date2025-09-15
Study Completion Date2026-12-09

Terms related to this study

Keywords Provided by Researchers

  • Hidradenitis suppurativa
  • skin disease
  • ruxolitinb cream

Additional Relevant MeSH Terms

  • Hidradenitis Suppurativa